CVAC Stock Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.25 |
| 52 Week High | US$20.60 |
| 52 Week Low | US$5.63 |
| Beta | 2.5 |
| 1 Month Change | 95.82% |
| 3 Month Change | 48.03% |
| 1 Year Change | -37.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.87% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Jan 27Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
Dec 23Shareholder Returns
| CVAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.6% | 0.7% | 2.3% |
| 1Y | -37.2% | 7.1% | -9.7% |
Return vs Industry: CVAC underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: CVAC underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| CVAC volatility | |
|---|---|
| CVAC Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CVAC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: CVAC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 824 | Franz-Werner Haas | https://www.curevac.com |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.
CureVac N.V. Fundamentals Summary
| CVAC fundamental statistics | |
|---|---|
| Market Cap | US$2.14b |
| Earnings (TTM) | -US$133.05m |
| Revenue (TTM) | US$105.58m |
20.3x
P/S Ratio-16.1x
P/E RatioIs CVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVAC income statement (TTM) | |
|---|---|
| Revenue | €96.96m |
| Cost of Revenue | €168.04m |
| Gross Profit | -€71.08m |
| Other Expenses | €51.10m |
| Earnings | -€122.18m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | -73.31% |
| Net Profit Margin | -126.02% |
| Debt/Equity Ratio | 0% |
How did CVAC perform over the long term?
See historical performance and comparison